17,261 trials
Psoriasis
Primary: Change in Severity of Psoriasis as Measured by Percentage Change in the Psoriasis Area and Severity Index (PASI) Instrument — 17.29; 27.06; 7.07; 20.02 Percent change in…
Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma · Stage IV Prostate Cancer AJCC v7
Primary: Gallium Ga 68-DOTATATE Uptake — 11; 4; 1 Participants
SARS-CoV-2
Primary: Parts A and B: Number of Participants With Solicited Local and Solicited Systemic Reactogenicity Adverse Reactions (ARs) — 30; 40; 37; 28 Participants
High Risk Myelodysplastic Syndrome
Primary: Number of Participants With a Complete Response (CR) — 25 Participants
Human Immunodeficiency Virus
Primary: Number of Participants With Solicited Adverse Events (AEs) Through 7 Days Post Dose 1 of Study Intervention — 155; 49; 132; 109 Participants
Severe Aplastic Anemia (SAA)
Primary: Complete Response (CR) Rate at Week 26 — 16.7; 25; 15.4; 0 percentage of participants
Heart Failure
Primary: Post-treatment Urine Output as Measured by Cumulative Urine Output Within 1 Day. — 34.0; 29.8; 22.6; 30.1 mL/mg
Dry Eye
Primary: Ocular Surface Disease Index (OSDI) — 48.9; 50.3 score on a scale
HIV-1-infection · Elevated Cardiovascular Risk
Primary: Change (Expressed as Ratio to Baseline) in 18-FDG-PET Target-to-background Ratio (TBR) of the Most Diseased Segment (MDS) of the Index (Most-inflamed) Vessel. — 0.95…
Forehead Lines
Primary: Number of Participants With Adverse Events — 10; 12; 18; 13 Participants
Nephrolithiasis
Primary: USSQ Urinary Symptom Score — 28; 29; 16; 17 score on a scale
Venous Thromboembolism
Primary: Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE) (REGN9933 vs Enoxaparin) — 17.2; 22.2 percentage of participants
Respiratory Syncytial Virus Infections
Primary: RSV-A Serum Neutralizing Titers Expressed As Mean Geometric Increase (MGI) Post-Dose 2 (Visit 4) Over Post-Dose 1 (Visit 3) for RSV_IC_2 Group — 1.34 Ratio
BCLC Stage B Hepatocellular Carcinoma · BCLC Stage C Hepatocellular Carcinoma · Hepatitis C Infection
Primary: Correlation of HCC Stiffness to Overall Survival — 0.12 kilopascals — p=0.008
Advanced Melanoma · Unresectable Melanoma
Primary: Overall Response Rate (ORR) — 10 percentage of patients